Sildenafil Citrate is used to treat erectile dysfunction (ED), which is a condition in which a man cannot achieve or maintain a penile erection for satisfactory sexual activity. When taking sildenafil citrate, it is recommended to only take it if directed by a doctor. You must follow the dosage instructions exactly and not to take it without medical advice. If you have taken a dose of Viagra, it is usually taken in the evening. If you take Viagra in the morning, the effects may be delayed until after a meal. Consult your doctor if you have a history of heart disease, high or low blood pressure, liver or kidney problems, heart rhythm disorders or a recent stroke or heart attack. It is best to avoid taking sildenafil citrate at any time of day, as it may interfere with other medications you are taking. It should not be taken more than once a day.
It is recommended to take sildenafil citrate by mouth as directed by your doctor. Do not take it with grapefruit or grapefruit juice. Avoid alcohol consumption while you are taking sildenafil citrate as it may increase the risk of side effects. Your blood pressure should be checked regularly and any side effects be immediately reported. The effects of this drug can last for several hours after you take it. If you have any medical conditions, you should not use this drug. Consult your doctor before taking sildenafil citrate. Sildenafil citrate may cause some side effects such as dizziness, fainting, and flushing. Some side effects may be rare but can be serious. If you experience any severe side effects, you should seek medical attention immediately. Before taking sildenafil citrate, tell your doctor if you have ever had an allergic reaction to this drug or any other medications. Do not take this drug if you are taking riociguat. If you have any liver or kidney problems, you should not take this drug. Consult your doctor before taking this medication.
Read moreIf you experience any serious side effects, you should seek medical attention immediately. If you have liver or kidney problems, you should not take this drug.
Viagra has been shown to cause some mild side effects. Talk to your health care provider if these do not go away within a few days. If you begin to experience more serious reactions, seek medical attention immediately.
Common side effects reported from Viagra use include:
More severe side effects include:
If you experience any of these side effects, seek medical attention immediately. These are symptoms of a severe adverse reaction to this medication that require immediate treatment.
As with all prescription medications, inform your doctor of any medical conditions you currently manage. Tell them about any and all medications, prescription drugs, and supplements you are taking before starting treatment with Viagra. Viagra can interact with bodily substances, causing potentially serious adverse reactions.
Specifically, you should inform your health care provider of any nitrate medication you are taking. Remember to mention any herbal products you use, especially St. John’s wort.
In addition, let your doctor know if you have recently had heart surgery or experience chest pain during sex. If you experience any changes in your heartbeat or chest pain during sex, contact your health care provider immediately.
asthma are complications suffered by youThis medication is used to treat symptoms of an enlarged prostate.
This medication can be used by adults and children 12 years and over.
arger quantities may be needed.
Do not take sildenafil if you:
If you have unexplained muscle aches or pains, get medical help right away
Use of this medication for medical reasons is not recommended.
HONG KONG, Oct. 1 (UPI) -- Pfizer Inc. said it plans to market its popular erectile dysfunction drug Viagra for retail pharmacies next month, the country's top drugmaker said Thursday.
In its announcement, Pfizer said it was working with a partner to market the drug in its stores, including in the US.
Viagra will be sold over-the-counter at pharmacies and online stores. The drug, which is sold under the brand name Cialis, has been linked to prostate cancer.
Pfizer has not disclosed when the launch date has been set.
Viagra, which treats erectile dysfunction, is an oral medication that works by increasing blood flow to the penis.
"Our goal is to provide men with the ability to achieve and maintain an erection whenever they are sexually stimulated, which is the goal of our current drug therapy," Pfizer said in a statement.
Pfizer also said it would continue selling the drug in the US.
Viagra, which comes in the form of a tablet, is available in 50 mg doses. It is the first pill approved for use in men, but it carries risks such as a rare heart problem that could lead to death.
Pfizer said it was working with its partner to create a generic version of the drug, which is called Revatio. The drug is designed for adults, but it has also been approved for use in some elderly patients, who may not have the same medical needs.
A spokesman for Pfizer said it did not know when a generic version of the drug, called generic sildenafil, will be made available.
Viagra is already available in many pharmacies in the US.
Pfizer said its decision to market the drug in the US was based on three factors: the company's patent for Viagra, its US launch date and its ability to produce a generic version.
Pfizer said it was working with other drugmakers to develop a generic version of the drug.
The drug, which is sold under the brand name Revatio, is designed for adult men with erectile dysfunction, but it has also been approved for use in some elderly patients, who may not have the same medical needs.
The drug's patent, which was first filed in 1994, was not set to expire in 2017.
Copyright © 2025 KLOE Consulting, LLC. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
KLOE ConsultingKLOE Consulting is a national consulting firm based in the United States. Our firm has offices in 25 countries and we are certified by the American Medical Association and the International Association of Boards of Pharmacy.
For more than 15 years, we have been a trusted partner in the global pharmaceutical industry. We work to support the healthcare industry to help improve the health and well-being of the nation's healthcare systems. We have a dedicated team of professionals, including doctors, pharmacists, nurses and pharmacists, who are dedicated to helping patients in the real-world setting, with the support of our client's peers and other organizations. We also offer a wide range of services, including patient assistance programs and support groups and a variety of educational seminars and events. For more information, visit us at.
KLOE Consulting is the leading global pharmaceutical consulting firm. We are in the process of developing a customized and user-friendly website that allows visitors to share their experiences and find information that is relevant to their health. Our website is designed to be a convenient, accessible resource for healthcare professionals and patients. By collaborating with our experts, patients can gain valuable information, make health decisions, and achieve better health care for their entire lives, including with the support of our network of over 40 partner organizations. KLOE Consulting is located in New York City and is part of the Global Health & Wellness Council.
KLOE Consulting is a registered trademark of KLOE Consulting LLC. In addition, this website and all information presented on our website may contain copyrighted educational material. We may not be able to provide the information that is essential for legal, ethical, and professional decisions about our company, which is owned by KLOE Consulting LLC.
For more information about our website, visit us at.
The first clinical trials in this area will be at a small-scale clinical trial in the West Midlands and Leicestershire, the University of Oxford and the University of Cambridge, the companies said.
The trial is being conducted at a small-scale clinical trial in the West Midlands and Leicestershire, the Department of Health said.
The trial, which was set up by the National Institute for Health Research to examine the effectiveness of an anti-impotence drug Viagra (sildenafil), will run from 5 July 2012 to 15 July 2013, with a follow-up run from 15 July 2013.
It will be run in collaboration with Pfizer, which is in the process of acquiring the rights to do so.
The study will be a phase 2 trial of Viagra for impotence, to assess its effectiveness in reducing duration and intensity of sexual intercourse, the company said.
It is the first phase 3 trial of sildenafil to treat impotence, which is caused by prostate enlargement.
The Viagra drug was developed by Pfizer in the late 1990s, but in the late 1990s it was sold by the drug company to treat erectile dysfunction.
It has been the subject of numerous clinical trials, which have looked at the drug's efficacy and safety.
In a separate study published in the November 2013 edition of theJournal of Sexual Medicine,one study found that the dose of the drug reduced the incidence of side-effects such as headaches and nausea, and of the side-effects such as loss of appetite and dizziness.
A similar trial in March, in which researchers looked at the efficacy of the drug on the incidence of side-effects, found that the dose of the drug reduced the incidence of side-effects such as visual disturbances.
The trial has been run since 2006.
The trial was launched in 1998 and the trial has since followed several subsequent trials, with Viagra being launched in the UK in 2002 as the first drug to be launched in the UK in the second half of the 20th century.
Pfizer, which is in the process of acquiring the patent for Viagra, is in the process of acquiring the rights for its drug and is planning to launch it in the UK next year.
It was the first clinical trial to examine the drug's effectiveness, which will run from 5 July 2012 to 15 July 2013, with a follow-up run from 15 July 2013.
The trial will also evaluate the effects of sildenafil, which is used to treat erectile dysfunction and pulmonary arterial hypertension, in a sample of people who have a family history of these conditions.
A second phase 3 trial, which will run from 20 April 2013 to 2 June 2013, will be run in partnership with the University of Cambridge, the companies said.
The trial is set to run from 27 June to 2 June 2013 in the area of sexual function and quality of life, as well as from 27 June to 4 June 2013 in the areas of psychosocial wellbeing and sexual wellbeing.
The drug is a phosphodiesterase type 5 (PDE5) inhibitor, used to treat erectile dysfunction.
It has been shown to be more effective in men aged 55 and older who have diabetes.
The company said the trial is "particularly important" for women who are unable to handle erections.
It is currently recruiting participants for an independent trial at the University of Cambridge.
The first clinical trials in the area of sexual function and quality of life will be conducted at a small-scale clinical trial in the West Midlands and Leicestershire, the university said.
The trial is being conducted at a small-scale clinical trial in the West Midlands and Leicestershire, the department of Health said.
The trial is being run at a small-scale clinical trial in the area of sexual function and quality of life.
The university is in the process of acquiring the rights to do so.The company said it had acquired the rights to do so.
The erectile dysfunction drug, Viagra, has been one of the world's top-selling medicines in recent years, having been approved for the treatment of the condition.
Stade de France Pharmacy